Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> PFIZER Latest News

JAN 24, 2013 - Benzinga

A Must Read - Share

Study Shows Higher Dose Of Toviaz (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder

Pfizer (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of ToviazĀ® (fesoterodine fumarate) 8 mg once daily in patients with overactive bladder (OAB) compared to Toviaz 4 mg once daily or placebo met its primary endpoint.

Tags: Study Shows Higher Dose Of Toviaz (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder,  Pfizer Latest News